Tyra Biosciences shares drop 22% after bladder cancer Phase 2 data
Tyra Biosciences stock fell 22% after Phase 2 trial data for dabogratinib in 44 adults with early-stage non-muscle invasive bladder cancer failed to inspire confidence.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.